Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...
Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...
The clinical spectrum of intestinal E. histolytica infection ranges from an asymptomatic carrier state to severe invasive disease. Asymptomatic cyst carriage occurs with E. histolytica as well as ...
Competing Interests: The author has been involved in clinical trials of albendazole and nitazoxanide, and has received research funding for these trials from SmithKline Beecham Pharmaceuticals and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results